AR065180A1 - Derivados de indol - 2 - il - piperazin - 1 - il - metanona y composicion farmaceutica - Google Patents

Derivados de indol - 2 - il - piperazin - 1 - il - metanona y composicion farmaceutica

Info

Publication number
AR065180A1
AR065180A1 ARP080100477A ARP080100477A AR065180A1 AR 065180 A1 AR065180 A1 AR 065180A1 AR P080100477 A ARP080100477 A AR P080100477A AR P080100477 A ARP080100477 A AR P080100477A AR 065180 A1 AR065180 A1 AR 065180A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogenoalkyl
alkoxy
halogen
substituted
Prior art date
Application number
ARP080100477A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR065180A1 publication Critical patent/AR065180A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de formula (1) son utiles para el tratamiento y/o la prevencion de enfermedades asociadas con la modulacion de receptores de H3, obesidad y otros trastornos. Reivindicacion 1: Compuestos de la formula general (1) en la que A es C(O) o S(O)2; R1 se elige entre el grupo formado por: alquilo inferior, alcoxi inferior, cicloalquilo, cicloalquilalquilo inferior, halogenoalquilo inferior, fenilo sin sustituir o sustituido de una a tres veces por grupos elegidos con independencia entre alquilo inferior, alcoxi inferior, halogeno, halogenoalquilo inferior y ciano, fenilalquilo inferior, cuyo anillo feniio puede estar sin sustituir o sustituido de una a tres veces por grupos elegidos con independencia entre alquilo inferior, alcoxi inferior, halogeno, halogenoalquilo inferior y ciano, -NR5R6, en el que R5 y R6 con independencia entre sí se eligen entre alquilo inferior, cicloalquilo, cicloalquilalquilo inferior, halogenoalquilo inferior y fenilalquilo inferior, o en el que R5 y R6 junto con el átomo de nitrogeno al que están unidos forman un anillo heterocíclico de 5 o 6 eslabones que contiene opcionalmente otro heteroátomo elegido entre nitrogeno, oxígeno y azufre; R2 se elige entre el grupo formado por hidrogeno, alquilo inferior, cicloalquilo, cicloalquilalquilo inferior, hidroxialquilo inferior, alcoxialquilo inferior, halogenoalquilo inferior, cianoalquilo inferior, alquilsulfonilo inferior, alcanoílo inferior, fenilsulfonilo, cuyo anillo fenilo puede estar sin sustituir o sustituido de una a tres veces por grupos elegidos con independencia entre alquilo inferior, halogeno, alcoxi inferior, halogenoalcoxi inferior e hidroxialquilo inferior, fenilo sin sustituir o sustituido de una a tres veces por grupos elegidos con independencia entre alquilo inferior, halogeno, ciano, morfolinilo, alcoxi inferior, (alcoxi inferior)-carbonilo, halogenoalquilo inferior, halogenoalcoxi inferior, hidroxialquilo inferior, alquilsulfonilo inferior y (alquilo inferior)-sulfonilamino, benzodioxolilo, fenilalquilo inferior, cuyo anillo fenilo puede estar sin sustituir o sustituido de una a tres veces por grupos elegidos con independencia entre alquilo inferior, halogeno, ciano, morfolinilo, alcoxi inferior, (alcoxi inferior)-carbonilo, halogenoalquilo inferior, halogenoalcoxi inferior, hidroxialquilo inferior, alquilsulfonilo inferior y (alquilo inferior)-sulfonilamino y heteroarilo sin sustituir o sustituido por uno o dos grupos elegidos con independencia entre alquilo inferior, alcoxi inferior, ciano, morfolinilo y halogeno; R3 se elige entre el grupo formado por hidrogeno, halogeno y metilo; R4 es un grupo elegido entre la formulas (2) en los que m es el numero 0 o 1; R7 se elige entre el grupo formado por alquilo inferior, cicloalquilo y halogenoalquilo inferior; R8 se elige entre el grupo formado por alquilo inferior, cicloalquilo y halogenoalquilo inferior; y sales farmacéuticamente aceptables de los mismos.
ARP080100477A 2007-02-07 2008-02-05 Derivados de indol - 2 - il - piperazin - 1 - il - metanona y composicion farmaceutica AR065180A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07101879 2007-02-07

Publications (1)

Publication Number Publication Date
AR065180A1 true AR065180A1 (es) 2009-05-20

Family

ID=39353037

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100477A AR065180A1 (es) 2007-02-07 2008-02-05 Derivados de indol - 2 - il - piperazin - 1 - il - metanona y composicion farmaceutica

Country Status (13)

Country Link
US (1) US7507736B2 (es)
EP (1) EP2118089B1 (es)
JP (1) JP2010518043A (es)
CN (1) CN101611027A (es)
AR (1) AR065180A1 (es)
AT (1) ATE467626T1 (es)
CA (1) CA2676265A1 (es)
CL (1) CL2008000365A1 (es)
DE (1) DE602008001249D1 (es)
ES (1) ES2342235T3 (es)
PE (1) PE20090115A1 (es)
TW (1) TW200840577A (es)
WO (1) WO2008095821A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006020482D1 (de) * 2005-11-30 2011-04-14 Hoffmann La Roche 1,5-substituierte indol-2-yl amidderivative
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
CN101796043A (zh) * 2007-07-25 2010-08-04 霍夫曼-拉罗奇有限公司 苯并呋喃-和苯并[b]噻吩-2-羧酸酰胺衍生物及其作为阻胺3受体调节剂的应用
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
GB0813144D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
CN105148896B (zh) * 2015-08-03 2017-09-22 贵州蓝天固废处置有限公司 一种废汞触媒中活性炭循环回收利用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000626D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
RU2365588C2 (ru) 2002-02-01 2009-08-27 Астразенека Аб Хиназолиновые соединения
US20040224952A1 (en) 2003-05-07 2004-11-11 Cowart Marlon D. Fused bicyclic-substituted amines as histamine-3 receptor ligands
MXPA05011942A (es) * 2003-05-07 2006-02-02 Abbott Lab Aminas sustituidas con biciclico fundido, como ligandos del receptor de histamina-3.
PL1761519T3 (pl) 2004-06-21 2008-09-30 Hoffmann La Roche Pochodne indolu jako antagoniści receptorów histaminowych
US20060069087A1 (en) 2004-09-27 2006-03-30 Pfizer Inc Histamine-3 receptor antagonists
DE602006014022D1 (de) 2005-11-30 2010-06-10 Hoffmann La Roche 5-substituierte indol-2-carbonsäureamidderivate
DE602006020482D1 (de) 2005-11-30 2011-04-14 Hoffmann La Roche 1,5-substituierte indol-2-yl amidderivative

Also Published As

Publication number Publication date
US20080188484A1 (en) 2008-08-07
CL2008000365A1 (es) 2008-08-08
PE20090115A1 (es) 2009-02-13
CN101611027A (zh) 2009-12-23
ES2342235T3 (es) 2010-07-02
EP2118089A1 (en) 2009-11-18
TW200840577A (en) 2008-10-16
DE602008001249D1 (de) 2010-06-24
CA2676265A1 (en) 2008-08-14
US7507736B2 (en) 2009-03-24
ATE467626T1 (de) 2010-05-15
EP2118089B1 (en) 2010-05-12
WO2008095821A1 (en) 2008-08-14
JP2010518043A (ja) 2010-05-27

Similar Documents

Publication Publication Date Title
AR059094A1 (es) Derivados de ciclohexil - sulfonamida
AR061486A1 (es) Derivados de 2-pirazinacarboxamida
AR049696A1 (es) Derivados de indol
AR065180A1 (es) Derivados de indol - 2 - il - piperazin - 1 - il - metanona y composicion farmaceutica
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
AR058984A1 (es) Derivados de ciclohexil piperazinil metanona
AR056883A1 (es) Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3
AR079334A1 (es) Derivados de oxazin amino
AR050281A1 (es) Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR057197A1 (es) Derivados de 1, 1-dioxo-tiomorfolinil-indolil-metanona
AR049433A1 (es) Derivados de naftalina
AR076170A1 (es) Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.
ES2572189T3 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis
AR059428A1 (es) Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende.
AR060405A1 (es) Compuestos organicos y sus usos en tratamientos de infeccion por el virus de hepatitis c
AR047958A1 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central.
AR054083A1 (es) Compuestos imidazol y su utilizacion paar preparar medicamentos
AR065181A1 (es) Derivados de 5 - amido - ( 1h -indol -2 -il ) - piperazin - 1 - il -metanona

Legal Events

Date Code Title Description
FB Suspension of granting procedure